TrueIP is a team of independent Australian based technical research and search professionals who have spent decades working at large branded Patent Attorney firms and Corporates conducting Patentability assessments, State of Art, Freedom to Operate, identifying licencing potential; IP gap analysis and due diligence research and searching services.
UniSA Ventures works with the University of South Australia to maximise the outcomes of intellectual property generated through research.
Universal Biosensors (UBI) is a medical diagnostics company focused on the research, development and manufacture of diagnostic test systems for point-of-care (POC) professional and home use. UBI has partnered with global healthcare company Siemens Healthcare Diagnostics to develop the Xprecia Stride blood coagulation analyser, launched in December 2014, to help patients taking the anticoagulant drug Warfarin manage their medication.
The University of Newcastle is a global leader distinguished by a commitment to equity and excellence. Its research is world-class and diverse as the university's partnerships and collaborations drive innovation.
UTS is a dynamic University, with the largest campus in the inner-city of Sydney.
USC Clinical Trials operates over an expanding network of dedicated clinical trial centres and private practice partnerships.
Vaxine was founded in 2002 as a spin out of the National Health Sciences Centre (NHSC) in Canberra to develop novel vaccine technologies. Vaxine is situated within the Flinders University precinct in Adelaide providing Vaxine with ideal opportunities for bench to bedside vaccine research and development.
Venture Technology Group (VTG) aspires to be the benchmark in the delivery of end to end professional service, advice, engagement and support to achieve successful development and commercialisation of drug, device and diagnostic assets globally.
The Vision Cooperative Research Centre (Vision CRC) Ltd was established in 2003 under the Australian Government's Business Cooperative Research Centres Programme and funded for twelve years, from 2003-2015.
VitalTrace is a medical device company aiming to improve outcomes for mothers and children during labour and delivery.
WE Buchan are an integrated public relations and communication agency, developing strategies that effectively cut through the clutter. Theycombine traditional and digital strategies to bring campaigns to life through meaningful brand engagement and exposure.
The Westmead Institute for Medical Research (WIMR) is one of the largest medical research institutes in Australia conducting research across infectious and immune diseases; cancer and leukaemia; liver and metabolic diseases; eye and brain related disorders and heart and respiratory disorders.
They are a proudly Australian owned and operated company committed to providing high quality and innovative technology at competitive prices sourced from all over the world.
MAESTrO is a large, comprehensive, on-line database of resources and submissions that display related outcomes for health care technologies of many types (medicine, vaccines, blood products, devices, procedures, cellular therapies and gene therapies) to the world's major regulatory and reimbursement/health technology agencies.
The Wound Management Innovation Cooperative Research Centre (WMI CRC) has been a catalyst for change in the wound industry since its inception in 2010.
Wrays is an independent IP specialist firm in Australia with significant experience in the recognition, protection and prosecution of intellectual property (IP) rights across a broad range of industries and technologies.
Xerion is dedicated to transforming innovations in life sciences into viable business opportunities that improves quality of life. The company currently has two major business units: a dermatology business and a medical device business.
Zucero Therapeutics is an Australian-based biotechnology company committed to the discovery and development of modified sugar compounds for the treatment of cancer. Pixatimod (PG545) has emerged as Zucero’s first clinical candidate and is classified as an immunomodulatory agent that enhances the host immune system’s ability to suppress cancer.